When to Consult with Your Healthcare Provider Persistent or Severe Nausea: If nausea is persistent, severe, or significantly impacting your quality of life, consult your healthcare provider
This is not a drug and so there are no known contradictions and precautions to be taken into consideration
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
We got an early start on a hot Friday morning in July
Try Two Timing Tightener alone or over any of our copper-peptide serums for an uplifting experience
For obese patients I think the initial focus should be on the patients with severe and morbid obesity first